MetaVia announced preclinical tissue distribution results for DA-1726, reporting that DA-1726-derived radioactivity was slowly absorbed and extensively distributed after subcutaneous dosing, with the highest exposure observed in adipose tissue (abdominal, subcutaneous and brown fat) and the liver.
Data showed tissue-to-plasma ratios increased over time, indicating prolonged retention through the final 144-hour assessment and a pharmacokinetic profile consistent with once-weekly dosing; only minimal radioactivity was detected in the central nervous system.
The company characterizes these findings as mechanistic support for a differentiated profile and links them to previously reported Phase 1 clinical observations in which a 48 mg dose produced a mean waist circumference reduction of 9.8 cm after eight weeks (Day 54).
MetaVia also notes that a 32 mg dose demonstrated best-in-class potential for weight loss, glucose control and waist reduction in its Phase 1 multiple ascending dose trial, and the company anticipates reporting 16-week topline data in the fourth quarter of 2026 followed by 24-week topline results in the first quarter of 2027.
DA-1726 is described as a once-weekly, subcutaneously administered oxyntomodulin analogue that acts as a GLP-1 receptor and glucagon receptor dual agonist and is being developed for obesity and metabolic dysfunction-associated steatohepatitis, with additional preclinical comparisons to existing agents cited by the company.
